TAO Synergies
1185 Avenue of the Americas, 3rd Floor, New York, 10036, United States
Overview
TAO Synergies is a company that recently completed a Series E financing. On or around October 15, 2025, the company raised $11 million in private capital by issuing 11,000 shares of Series E convertible preferred stock. The company has not publicly detailed its core product or service, but investor demand enabled a sizable late-stage round. The new funding strengthens TAO Synergies’ balance sheet ahead of its next phase of growth. Interest in the broader TAO ecosystem was evident when Bittensor hosted meetups in Shenzhen and Hong Kong on October 25-26, 2025, bringing together TAO token users, builders, and investors anticipating news that could influence TAOBUSD prices. No revenue, user, or other operating metrics were disclosed in the available information.
- Total raised
- $11M
- Funding rounds
- 1
- Latest round
- Series E
- Latest activity
- Oct 2025
Industries
- Biopharma
- Biotechnology
- Pharmaceutical
Recent funding
Series E
Oct 2025
$11M
Team
Alan Tuchman
Chief Executive Officer
Daniel Alkon
President & Chief Scientific Officer
James Altucher
lead TAO
LinkedInRobert Weinstein
Chief Financial Officer